We show that constitutive and inducible deregulation of TGFβ-SMAD2/3 pro-fibrotic network—a key component of DMD pathogenesis [3, 17–19]—is recapitulated in our system and can be used to screen for compounds with therapeutic potential in DMD. The gene discussed is SMAD2; the disease is Duchenne muscular dystrophy.